Farias JG, Puebla M, Acevedo A, Tapia PJ, Gutierrez E, Zepeda A, et al
The substance liraglutide, under the brand name Saxenda, was introduced to the market in 2015 as the first GLP-1 RA approved as a treatment complementary to exercise and diet for weight control in patients with high BMI (obese or overweight with weight-related comorbidities) [3]
The occurrence of amyloid-related imaging abnormalities (ARIA) in the context of treatment with anti-amyloid monoclonal antibodies has drawn attention to the importance of vascular pathology in the pathogenesis and treatment of AD [105]
10.1038/s41422-020-0343-4 57 HilliganK
This time is defended by major hormonal fluctuations, increased prolactin, and often significant sleep disruption, which makes the body more sensitive overall
Slides were dried at room temperature overnight for imaging